Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

722.75INR
2 Mar 2015
Change (% chg)

Rs11.35 (+1.60%)
Prev Close
Rs711.40
Open
Rs715.00
Day's High
Rs728.90
Day's Low
Rs708.90
Volume
87,766
Avg. Vol
88,929
52-wk High
Rs746.00
52-wk Low
Rs335.00

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.54
Market Cap(Mil.): Rs292,728.81
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 38.87 40.17
EPS (TTM): -19.13 -- --
ROI: -- 16.97 16.27
ROE: -- 17.50 17.24
Search Stocks

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed.

28 Feb 2015

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed.

28 Feb 2015

U.S. judge denies Ranbaxy bid to reinstate approvals for Valcyte, Nexium copies

MUMBAI, Feb 28 - A U.S. federal judge has denied Indian generic drugmaker Ranbaxy Laboratories Ltd's bid to reinstate approvals granted to it to launch the first copies of the heartburn drug Nexium and the antiviral Valcyte, a court document showed.

28 Feb 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

UPDATE 1-Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sells its interest in a generic anti-bacterial medicine, the Federal Trade Commission said on Friday.

31 Jan 2015

Ranbaxy Dec-quarter net loss widens on forex loss

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd reported a wider loss in the December quarter, hurt by foreign exchange losses and higher finance costs.

28 Jan 2015

India's Ranbaxy Dec qtr net loss widens on forex loss

MUMBAI, Jan 28 - Indian generic drugmaker Ranbaxy Laboratories Ltd reported a wider loss in the December quarter, hurt by foreign exchange losses and higher finance costs.

28 Jan 2015

Nifty falls to one-month low, tracking weak China

MUMBAI - The Nifty fell for a third consecutive day on Tuesday, closing at a one-month low, as investors cashed out positions tracking a selloff in Chinese markets, hurting blue-chips such as Oil and Natural Gas Corp.

09 Dec 2014

Earnings vs. Estimates

Search Stocks